TRANSMEDICS GROUP INC

Inside insider buying at TransMedics signals leadership confidence in its transplant‑therapy pipeline and a potential upside despite biotech volatility.

Insider Thomas Gunderson’s June 15 trade shows strong confidence in TransMedics Group: buying options‑derived shares at $2.21 while selling 9,624 shares at $75.06, hinting at a bullish outlook amid rising stock and positive insider buying trend.

Insider buying at TransMedics signals confidence in its transplant tech pipeline, offering investors a potential catalyst for valuation reassessment.

Inside TransMedics CFO Gerardo Hernandez’s March 2026 trades show strategic liquidity, confidence in rising valuations, and a disciplined approach to funding growth without diluting ownership.

TransMedics insider selling: Anil P. sells 864 shares at $139.12. Explore what this liquidity move means for investors and the company’s growth outlook.